2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
January 28th 2016
Steven I. Park, MD, director, Lymphoma Program, associate professor of Medicine, Leukemia, Lymphoma, and Myeloma Program, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Clinical Research, discusses how alisertib induces synthetic lethality and overcomes chemoresistance in Myc-overexpressing lymphoma cells.